We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01845584
First Posted: May 3, 2013
Last Update Posted: April 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Nihon Pharmaceutical Co., Ltd
  Purpose

Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive steroid plus therapy (1g/day for five consecutive days). Subsequently, patients who not provided adequate effect of therapy to steroids plus therapy will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluated Quantification of nerve and spinal cord impairment (QOSI) and the Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) and anti-aquaporin 4 antibody et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.


Condition Intervention Phase
Neuromyelitis Optica Spectrum Disorder Drug: NPB-01 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Resource links provided by NLM:


Further study details as provided by Nihon Pharmaceutical Co., Ltd:

Primary Outcome Measures:
  • Change from Baseline Quantification of nerve and spinal cord impairment (QOSI) at 29 days [ Time Frame: 29 days ]
  • Change from Baseline Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) at 29 days [ Time Frame: 29 days ]
  • Change from Baseline anti-aquaporin 4 antibody at 29 days [ Time Frame: 29 days ]

Enrollment: 7
Actual Study Start Date: May 2013
Study Completion Date: August 2015
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NPB-01
Intravenous immunoglobulin
Drug: NPB-01
Other Name: Intravenous immunoglobulin

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who become positive for anti-aquaporin 4 antibody or have becomed.
  2. Patients who have developed myelitis.
  3. Patients who run beyond greater than 30 days at least from last time in relapse.
  4. Patients who new neurological symptom or worsening neurological symptom or flared neurological symptom have sustained 24 hours at least not associated fever or infection.
  5. Patients who have an acute exacerbation at informed consent.
  6. Patients who need steroid plus therapy(1g/day for five consecutive days).
  7. Patients who can start steroid plus therapy within 3 days after informed consent.
  8. Patients who be inadequate to effect to steroid plus therapy.
  9. Patients with greater than or equal to twenty years old at informed consent.

Exclusion Criteria:

  1. Patients who have developed optic neuritis.
  2. Patients treated with intravenous immunoglobulin within 14 days before informed consent.
  3. Patients with malignancy at informed consent.
  4. Patients with history of shock or hypersensitivity for NPB-01.
  5. Patients with IgA deficiency.
  6. Patients with impaired liver function.
  7. Patients with impaired renal function.
  8. Patients with cerebro- or cardiovascular disorders.
  9. Patients with high risk of thromboembolism.
  10. Patients with hemolytic/hemorrhagic anemia.
  11. Patients with decreased cardiac function.
  12. Patients with decreased platelet.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01845584


Locations
Japan
Japan
Osaka,, Japan
Sponsors and Collaborators
Nihon Pharmaceutical Co., Ltd
  More Information

Responsible Party: Nihon Pharmaceutical Co., Ltd
ClinicalTrials.gov Identifier: NCT01845584     History of Changes
Other Study ID Numbers: NPB-01-08/E-01
First Submitted: April 26, 2013
First Posted: May 3, 2013
Last Update Posted: April 12, 2017
Last Verified: April 2017

Keywords provided by Nihon Pharmaceutical Co., Ltd:
IVIG in Neuromyelitis Optica spectrum disorder
Patients with Neuromyelitis Optica spectrum disorder

Additional relevant MeSH terms:
Disease
Neuromyelitis Optica
Pathologic Processes
Myelitis, Transverse
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Optic Neuritis
Optic Nerve Diseases
Cranial Nerve Diseases
Demyelinating Diseases
Eye Diseases
Autoimmune Diseases
Immune System Diseases
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
gamma-Globulins
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs